Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome

2011 ◽  
Vol 6 (1) ◽  
Author(s):  
Farid Saad ◽  
Ahmad Haider ◽  
Erik J. Giltay ◽  
Louis J.G. Gooren
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Body Mass ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Serum Testosterone ◽  
Waist Size ◽  
The Metabolic Syndrome ◽  
Testosterone Administration

AbstractTestosterone administration to hypogonadal men improves the metabolic syndrome. This study analyzed whether age, serum testosterone, body mass index/waist circumference, increment in testosterone values and C-reactive protein (CRP) predicted the outcome of testosterone administration.A total of 110 mainly elderly men, aged between 18 and 83 years (mean±SD=59.6±8.0) with baseline serum testosterone of 5.8–12.1 nmol/L (mean±SD=9.3±1.7) (n>14.0 nmol/L), received parenteral testosterone undecanoate whereupon serum testosterone normalized between 3 and 24 months.(i) The lower the baseline testosterone, the stronger the decreases in waist size and triglycerides. (ii) The greater the increment in serum testosterone, the stronger the decreases in low-density lipoprotein (LDL) cholesterol, triglycerides and glucose. (iii) Older age was associated with stronger beneficial effects on waist size, glucose and all lipids, but a small negative effect on high-density lipoprotein cholesterol. (iv) Obese men and men with the largest waist circumference showed the strongest declines over 2 years in weight, waist circumference and body mass index (BMI), and also in total cholesterol, triglycerides and glucose. Baseline BMI predicted a stronger decline in LDL cholesterol, but a smaller decline in CRP levels. (v) Higher baseline CRP predicted larger declines in levels of triglycerides, glucose and CRP. (vi) In the multivariate model, age, BMI and CRP were independent predictors of the strongest benefit of testosterone treatment on the metabolic syndrome.Older men, particularly when obese with chronic low-grade inflammation benefited most of normalizing their testosterone levels, preferably if they reached mid-normal reference values.

Abstract P250: How to Successfully Manage Adolescents’ Metabolic Syndrome. Keep it Simple!

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Julie St-Pierre ◽  
Charles B Thibault ◽  
Johanne Harvey ◽  
Helene Fortin ◽  
JoAnnie Lapointe ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Motivational Interviewing ◽  
Body Mass ◽  
Weight Reduction ◽  
Lifestyle Changes ◽  
The Metabolic Syndrome ◽  
Family Approach

Background: The metabolic syndrome prevalence in adolescents is still rising (with up to 8% in some populations); this increase is mainly attributable to the obesity epidemic. Consequently, the long-term cardiovascular risk of these adolescents is very high. Unfortunately, despite this elevated risk, motivation and adherence to weight reduction programs still remain very low. Hypothesis: To verify if the combination of motivational interviewing, nutritional and physical education, and a close follow-up in a multidisciplinary, family-based weight-reduction pediatric clinic is effective to initiate and sustain beneficial lifestyle changes at 6 months. Subjects and Method: Fifty (50) families with adolescents (10-17 years old) characterized by obesity and metabolic syndrome were recruited with their families. The cardiometabolic risk profile (including body mass index, waist circumference, blood pressure, glucose, insulin, lipids and apolipoprotein B levels) of every subject was evaluated and explained to the adolescent and his/her parents. With motivational interviewing techniques and educative approaches, adolescents were brought to set up, at the first visit, a one month, one health challenge change. In subsequent visits, anthropometric measurements were recorded and, based on their first month’s success, new healthy challenges were proposed by the adolescent. Results: Adolescents participating in this program were initially highly motivated to initiate a one month healthy challenge with an average score of 7/10. Eighty percent of them chose to stop drinking juice or soda beverages as their first challenge. At one month, over 80% of them observe a weight reduction or no weight gain. At this point, the adolescents’ perception of success is the main source of motivation to introduce new health challenges in their life. At 3 and 6 months, healthy habits are still present in over 70% of them. Interestingly, these changes are accompanied by modifications in anthropometric covariables. At 6 months, we observe a significant reduction of body mass index (p=0.027) and waist circumference (p=0.047) in addition to a trend towards a reduction of mean weight (p=0.054). Conclusion: With counselling based on education, motivational techniques and a family approach, a high proportion of adolescents have initiated and maintained healthy changes. At 6 months, waist circumference reduction was the strongest change. This combined familial approach appears promising to reduce metabolic syndrome prevalence in adolescents. The prospective data collection is still ongoing, with the first adolescents recruited now reaching the one-year follow-up.

scholarly journals Monitoring of the Metabolic Syndrome in Psychiatric Inpatients

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
J. Cordes ◽  
G. Regenbrecht ◽  
M.W. Agelink ◽  
J. Zielasek ◽  
K.G. Kahl
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Body Mass ◽  
Visceral Fat ◽  
Inpatient Treatment ◽  
Fasting Glucose ◽  
The Body ◽  
The Metabolic Syndrome ◽  
Increased Risk

In this naturalistic observational study carried out in an inpatient treatment setting we as yet surveyed the parameters of the metabolic syndrome. A weekly monitoring procedure was implemented. The analysis included data of 350 patients over a time of 12 weeks. The last observation carried forward method was applied. Additionally we are evaluating the informative value of visceral body fat percentage as measured by a body composition analyzer. The patients showed a weight increase over the first 12 weeks (mean increase: 0.87 kg, p < .001) as well as an increase of the body mass index (mean increase: 0.45 kg/m2, p < .001). Accordingly, waist circumference (mean increase: 1.06 cm, p = .007) and visceral fat index (mean increase: 0.19, p = .007) increased. No worsening of fasting glucose and blood lipid concentrations was detected. Spearmens coefficient indicated correlations between visceral fat index and body mass index (ρ = .77; p < .001), waist circumference (ρ = .70; p < .001), and triglyceride concentrations (ρ = .39; p < .001). Correlations between visceral fat index and fasting glucose (ρ = .18; p = .019), and visceral fat index and total cholesterol (ρ = .16; p = .049) were weak but also significant. In contrast, the HDL cholesterol showed a negative relation with ρ < -.39 at each point in time (p < .001).We conclude that psychiatric patients are at increased risk for the development of metabolic alterations during inpatient treatment. The possible underlying mechanisms of this interaction are discussed.

scholarly journals The Metabolic Syndrome among Postmenopausal Women in Gorgan

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Abdoljalal Marjani ◽  
Sedigheh Moghasemi
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Postmenopausal Women ◽  
Body Mass ◽  
Hdl Cholesterol ◽  
Waist To Hip Ratio ◽  
Positive Correlation ◽  
The Metabolic Syndrome ◽  
The Mean

Introduction. The present study aimed to assess the metabolic syndrome among postmenopausal women in Gorgan, Iran.Materials and Methods. The study was conducted on hundred postmenopausal women who were referred to the health centers in Gorgan. Metabolic syndrome was diagnosed using Adult Treatment Panel III (ATP III) guidelines.Results. The mean body mass index, waist circumference, hip, circumference waist-to-hip ratio, diastolic blood pressure, and triglyceride and fasting blood glucose levels were significantly high among postmenopausal women with metabolic syndrome, but the mean HDL-cholesterol was significantly low (P<0.05). Overall prevalence of metabolic syndrome was 31%. Body mass index and waist circumference had a positive correlation with a number of metabolic syndrome factors (P<0.001). Body mass index, waist circumference, and waist-to-hip ratio had a positive correlation with each other (P<0.001). BMI had relatively high correlation with WC (P<0.001).Conclusions. Our results show that postmenopausal status might be a predictor of metabolic syndrome. Low HDL-cholesterol level and high abdominal obesity are the most frequent characteristics in comparison to other metabolic components. Our study also showed some related factors of metabolic syndrome among postmenopausal women. These factors may increase cardiovascular risk among postmenopausal women with metabolic syndrome.

scholarly journals The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome

2010 ◽  
Vol 63 (9-10) ◽  
pp. 611-615 ◽  
Author(s):  
Branka Koprivica ◽  
Teodora Beljic-Zivkovic ◽  
Tatjana Ille
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Glycemic Control ◽  
Body Mass ◽  
Combined Therapy

Introduction. Insulin resistance is a well-known leading factor in the development of metabolic syndrome. The aim of this study was to evaluate metabolic effects of metformin added to sulfonylurea in unsuccessfully treated type 2 diabetic patients with metabolic syndrome. Material and methods. A group of thirty subjects, with type 2 diabetes, secondary sulfonylurea failure and metabolic syndrome were administered the combined therapy of sulfonylurea plus metformin for six months. Metformin 2000 mg/d was added to previously used sulfonylurea agent in maximum daily dose. Antihypertensive and hypolipemic therapy was not changed. The following parameters were assessed at the beginning and after six months of therapy: glycemic control, body mass index, waist circumference, blood pressure, triglycerides, total cholesterol and its fractions, homeostatic models for evaluation of insulin resistance and secretion (HOMA R, HOMA B) and C- peptide. Results. Glycemic control was significantly improved after six months of the combined therapy: (fasting 7.89 vs. 10.61 mmol/l. p<0.01; postprandial 11.12 vs. 12.61 mmol/l. p<0.01, p<0.01; glycosylated hemoglobin 6.81 vs. 8.83%. p<0.01). the body mass index and waist circumference were significantly lower (26.7 vs. 27.8 kg/m2, p<0.01 and 99.7 vs. 101.4 cm for men, p<0.01; 87.2 vs. 88.5 for women, p<0.01). Fasting plasma triglycerides decreased from 3.37 to 2.45 mmol/l (p<0.001) and HOMA R from 7.04 to 5.23 (p<0.001). No treatment effects were observed on blood pressure, cholesterol, and residual insulin secretion. Conclusion. Administration of metformin in type 2 diabetes with metabolic syndrome decreased cardiovascular risk factors by reducing glycemia, triglycerides, BMI, central obesity and insulin resistance.

scholarly journals Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome

2013 ◽  
Vol 98 (12) ◽  
pp. 4899-4907 ◽  
Author(s):  
Kyung Hee Park ◽  
Lesya Zaichenko ◽  
Mary Brinkoetter ◽  
Bindiya Thakkar ◽  
Ayse Sahin-Efe ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Body Mass ◽  
Model Assessment ◽  
Homeostasis Model Assessment ◽  
Cvd Risk ◽  
Baseline Serum ◽  
The Metabolic Syndrome ◽  
Increased Risk

Context: Irisin, a recently identified hormone, has been proposed to regulate energy homeostasis and obesity in mice. Whether irisin levels are associated with risk of the metabolic syndrome (MetS), cardiometabolic variables, and cardiovascular disease (CVD) risk in humans remains unknown. Objective: Our objective was to assess the associations between baseline serum irisin levels and MetS, cardiometabolic variables, and CVD risk. Design, Setting, and Subjects: We conducted a comparative cross-sectional evaluation of baseline circulating levels of the novel hormone irisin and the established adipokine adiponectin with MetS, cardiometabolic variables, and CVD risk in a sample of 151 subjects. Results: Baseline irisin levels were significantly higher in subjects with MetS than in subjects without MetS. Irisin was associated negatively with adiponectin (r = −0.4, P &lt; .001) and positively with body mass index (r = 0.22, P = .008), systolic (r = 0.17, P = .04) and diastolic (r = 0.27, P = .001) blood pressure, fasting glucose (r = 0.25, P = .002), triglycerides (r = 0.25, P = .003), and homeostasis model assessment for insulin resistance (r = 0.33, P &lt; .001). After adjustment for potential confounders, including body mass index, subjects in the highest tertile of irisin levels were more likely to have MetS (odds ratio [OR] = 9.44, 95% confidence interval [CI] = 2.66–33.44), elevated fasting blood glucose (OR = 5.80, 95% CI = 1.72–19.60), high triglycerides (OR = 3.89, 95% CI = 1.16–13.03), and low high-density lipoprotein cholesterol (OR = 3.30, 95% CI = 1.18–9.20). Irisin was independently associated with homeostasis model assessment for insulin resistance and general Framingham risk profile in multiple linear regression analyses after adjustment for confounders. Adiponectin demonstrated the expected associations with outcomes. Conclusions: Irisin is associated with increased risk of MetS, cardiometabolic variables, and CVD in humans, indicating either increased secretion by adipose/muscle tissue and/or a compensatory increase of irisin to overcome an underlying irisin resistance in these subjects.

scholarly journals A Three-Month Consumption of Eggs Enriched with ω-3, ω-5 and ω-7 Polyunsaturated Fatty Acids Significantly Decreases the Waist Circumference of Subjects at Risk of Developing Metabolic Syndrome: A Double-Blind Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 663
Author(s):  
Monique T. Ngo Njembe ◽  
Barbara Pachikian ◽  
Irina Lobysheva ◽  
Nancy Van Overstraeten ◽  
Louis Dejonghe ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
At Risk ◽  
Randomized Controlled Trial ◽  
Waist Circumference ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Test Group ◽  
Double Blind ◽  
Randomized Controlled ◽  
The Metabolic Syndrome

Alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), rumenic acid (RmA), and punicic acid (PunA) are claimed to influence several physiological functions including insulin sensitivity, lipid metabolism and inflammatory processes. In this double-blind randomized controlled trial, we investigated the combined effect of ALA, DHA, RmA and PunA on subjects at risk of developing metabolic syndrome. Twenty-four women and men were randomly assigned to two groups. Each day, they consumed two eggs enriched with oleic acid (control group) or enriched with ALA, DHA, RmA, and PunA (test group) for 3 months. The waist circumference decreased significantly (−3.17 cm; p < 0.001) in the test group. There were no major changes in plasma insulin and blood glucose in the two groups. The dietary treatments had no significant effect on endothelial function as measured by peripheral arterial tonometry, although erythrocyte nitrosylated hemoglobin concentrations tended to decrease. The high consumption of eggs induced significant elevations in plasma low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol (p < 0.001), which did not result in any change in the LDL/HDL ratio in both groups. These results indicate that consumption of eggs enriched with ALA, DHA, RmA and PunA resulted in favorable changes in abdominal obesity without affecting other factors of the metabolic syndrome.

scholarly journals Insulin resistance in relation to clinical, endocrine and metabolic profile of infertile women with polycystic ovary syndrome

2021 ◽  
Vol 14 (1) ◽  
pp. 1-6
Author(s):  
Shakeela Ishrat ◽  
Marufa Hossain ◽  
Subrata Kumar Biswas
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Polycystic Ovary Syndrome ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Significant Difference

The objective of this study is to explore how hyperinsulinemia and insulin resistance relate to the clinical, endocrine and metabolic factors in the infertile women with polycystic ovary syndrome. This study was conducted on 121 consecutive infertile women with polycystic ovary syndrome attending the Infertility unit from January 2017 to December 2017. They were divided into two groups: insulin resistant and insulin sensitive. There was significant difference in body mass index and waist circumference between the two groups. Serum lipids were not associated with insulin resistance. Hyperinsulinemia was significantly associated with metabolic syndrome. Reducing body mass index and waist circumference may improve insulin resistance in infertile women with polycystic ovary syndrome. Screening the infertile women with polycystic ovary syndrome for hyperinsulinemia and insulin resistance and subsequent counseling is recommended to address the long-term risks of metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document